Fresh from a Pfizer buyout, Luca Santarelli’s crew has created a new company — banking new funds and steering their lead drug to a pivotal

John Carroll

Editor & Founder

Almost exactly 3 years since he joined the biotech startup world as head of Therachon, the high-profile discovery scientist Luca Santarelli is ready to start …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Fresh from a Pfizer buyout, Luca Santarelli’s crew has created a new company — banking new funds and steering their lead drug to a pivotal

John Carroll

Editor & Founder

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Biotech seed rounds sink to lowest level in years as industry slump drags on

US drugs rely heavily on ingredients made overseas, new report shows

Pharma's wins and losses in Trump's sprawling executive order on drug prices

Sanofi to pay $125M upfront for two immunology drugs from little-known biotech

Trump pledges his support for a change to the IRA long sought by drugmakers

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

Fresh from a Pfiz­er buy­out, Lu­ca Santarel­li’s crew has cre­at­ed a new com­pa­ny — bank­ing new funds and steer­ing their lead drug to a piv­otal

Editor & Founder

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Fresh from a Pfizer buyout, Luca Santarelli’s crew has created a new company — banking new funds and steering their lead drug to a pivotal